Customized phage therapies to eradicate
harmful bacteria in chronic diseases
Featured Highlights
BiomX Key Opinion Leader Symposium on BX001 for Acne
December 15, 2019
BiomX News
BiomX to Present at Upcoming September Investor Conferences
Event: HC Wainwright 22nd Annual Global Investments Conference
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
BiomX XMarker biomarker discovery platform to potentially inform Boehringer Ingelheim’s development of IBD therapeutics
BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update
– Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expected by the end of 2020
– On track for Phase 2 cosmetic clinical study of BX001 in acne first quarter of 2021
– Cash and equivalents of $70.6 million expected to fund current operating plan through mid-2022
– Company to host conference call today at 8:00 a.m. Eastern Time
OUR INVESTORS
